Fol­low­ing a win for Baven­cio, Pfiz­er and Mer­ck KGaA con­tin­ue PD-L1 los­ing streak

Last month
Pharma
R&D

Monopar de­lays IPO again de­spite slash­ing of­fer­ing while a mi­cro-cap biotech clinch­es $9M

Last month
IPOs

Tri­fec­ta of in­com­ing mi­graine meds must be cheap­er than trip­tans to be cost-ef­fec­tive — ICER

Last month
Pharma

Roche aban­dons an­ti-myo­statin ap­proach to Duchenne MD — one more nail in the class' cof­fin

Last month
R&D

Some bat­tle test­ed neu­ro­science vets are go­ing all out on ear­ly on­set de­men­tia — with a $44M launch round to build the team

Last month
R&D
Startups

HHS is tak­ing Gilead to court, seek­ing dam­ages for in­fring­ing gov­ern­ment HIV patents

Last month
Pharma
Regulatory

Re­genxBio runs in­to par­tial hold for an­ti-VEGF gene ther­a­py as FDA in­ves­ti­gates de­liv­ery de­vice

Last month
Cell/Gene Tx
Regulatory

George Church start­up eGe­n­e­sis rakes $100M to ramp up CRISPR pig or­gan trans­plants

Last month
Venture

As­traZeneca sketch­es plans for a $1B ven­ture fund — and it's go­ing to Chi­na

Last month
China
Venture

On the heels of a $6.9B As­traZeneca pact, IP dis­pute be­tween Dai­ichi Sankyo and Seat­tle Ge­net­ics rips open in law­suit

Last month
Pharma
R&D

An­oth­er ex-Shire re­search ex­ec heads out, grab­bing top R&D job at deal-hun­gry Ipsen as post-buy­out ex­o­dus con­tin­ues

Last month
People
R&D

Andy Plump teams with MD An­der­son on the race to cell ther­a­py 2.0 — and they’re al­ready plan­ning a piv­otal

Last month
Deals
R&D

Unum drops an­oth­er pro­gram for trou­bled PhI ther­a­py, mov­ing its eggs to the sol­id tu­mor bas­ket

Last month
R&D

Make room for poop trans­plants, even if a stool-based ther­a­py is even­tu­al­ly ap­proved — in­sist doc­tors and pa­tients in FDA hear­ing

Last month
Regulatory

As­traZeneca wins ku­dos for pipeline turn­around in a new rank­ing of the top 10 R&D play­ers in the bio­phar­ma world

Last month
Pharma
R&D

Halozyme's lead drug flops in PhI­II, forc­ing CEO to ax 160 and re­set fo­cus on tech plat­form

Last month
R&D

Alzheimer's stun­ner: Chi­nese biotech wins OK for a new drug on pos­i­tive da­ta — and they have some high-pro­file sup­port­ers

Last month
China
Regulatory

Da­ta sug­gest gene, cell ther­a­py tri­al ini­ti­a­tions in Eu­rope lag be­hind North Amer­i­ca — here's why

Last month
R&D
Regulatory

Eight years af­ter a land­mark buy­out, Sanofi agrees to pay ag­griev­ed Gen­zyme share­hold­ers $315M to set­tle foot-drag­ging claims

Last month
Pharma
R&D

Am­gen takes a $2.7B stake in BeiGene, gain­ing a promi­nent al­ly in Chi­na to help seize a lead­ing role in can­cer drug com­mer­cial­iza­tion and de­vel­op­ment

Last month
China
Deals

Sanofi's on­col­o­gy R&D group marks a pair of set­backs on isat­ux­imab/Lib­tayo com­bo as can­cer stud­ies fiz­zle out

Last month
R&D

Oz Azam beefs up Tmu­ni­ty's to­tal raise to $231M as they steer to­ward hu­man da­ta in the dri­ve to cell ther­a­py 2.0

Last month
R&D

Roche signs up Dicer­na in a $200M-plus cash al­liance to help de­vel­op a hep B cock­tail, cap­ping the biotech's big year

Last month
Deals

Pe­ter Hecht’s Iron­wood spin­out fails back-to-back stud­ies on a key drug, crush­ing shares and trig­ger­ing cut­backs — but he still sees a path for­ward

Last month
R&D
First page Previous page 1234567 Next page Last page